These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24003937)

  • 21. A biphasic role of nuclear transcription factor (NF)-kappaB in the islet beta-cell apoptosis induced by interleukin (IL)-1beta.
    Papaccio G; Graziano A; D'Aquino R; Valiante S; Naro F
    J Cell Physiol; 2005 Jul; 204(1):124-30. PubMed ID: 15622524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes.
    Leiter LA
    Diabet Med; 2005 Aug; 22(8):963-72. PubMed ID: 16026359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there a role for immune and anti-in-flammatory therapy in type 2 diabetes?
    Sathyapalan T; Atkin SL
    Minerva Endocrinol; 2011 Jun; 36(2):147-56. PubMed ID: 21519323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macrophages, cytokines and beta-cell death in Type 2 diabetes.
    Ehses JA; Böni-Schnetzler M; Faulenbach M; Donath MY
    Biochem Soc Trans; 2008 Jun; 36(Pt 3):340-2. PubMed ID: 18481953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulitis in type 2 diabetes.
    Böni-Schnetzler M; Ehses JA; Faulenbach M; Donath MY
    Diabetes Obes Metab; 2008 Nov; 10 Suppl 4():201-4. PubMed ID: 18834448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of multiple low-dose streptozotocin (MLD-STZ) diabetes in mice by an extract from gum resin of Boswellia serrata (BE).
    Shehata AM; Quintanilla-Fend L; Bettio S; Singh CB; Ammon HP
    Phytomedicine; 2011 Sep; 18(12):1037-44. PubMed ID: 21831620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation by cytokines of the inducible nitric oxide synthase promoter in insulin-producing cells.
    Darville MI; Eizirik DL
    Diabetologia; 1998 Sep; 41(9):1101-8. PubMed ID: 9754830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-1 beta targeted therapy for type 2 diabetes.
    Maedler K; Dharmadhikari G; Schumann DM; Størling J
    Expert Opin Biol Ther; 2009 Sep; 9(9):1177-88. PubMed ID: 19604125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm.
    Green J; Feinglos M
    Int J Clin Pract Suppl; 2007 Aug; (154):3-11. PubMed ID: 17593272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.
    Abdin AA; Baalash AA; Hamooda HE
    J Diabetes Complications; 2010; 24(3):168-78. PubMed ID: 19328014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes.
    Donath MY; Böni-Schnetzler M; Ellingsgaard H; Ehses JA
    Physiology (Bethesda); 2009 Dec; 24():325-31. PubMed ID: 19996363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetes mellitus-associated periodontitis: differences between type 1 and type 2 diabetes mellitus.
    Aspriello SD; Zizzi A; Tirabassi G; Buldreghini E; Biscotti T; Faloia E; Stramazzotti D; Boscaro M; Piemontese M
    J Periodontal Res; 2011 Apr; 46(2):164-9. PubMed ID: 21108647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction.
    Westwell-Roper C; Dai DL; Soukhatcheva G; Potter KJ; van Rooijen N; Ehses JA; Verchere CB
    J Immunol; 2011 Sep; 187(5):2755-65. PubMed ID: 21813778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity.
    Donath MY; Dalmas É; Sauter NS; Böni-Schnetzler M
    Cell Metab; 2013 Jun; 17(6):860-872. PubMed ID: 23747245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments.
    Antar SA; Ashour NA; Sharaky M; Khattab M; Ashour NA; Zaid RT; Roh EJ; Elkamhawy A; Al-Karmalawy AA
    Biomed Pharmacother; 2023 Dec; 168():115734. PubMed ID: 37857245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes.
    Böni-Schnetzler M; Donath MY
    Br J Clin Pharmacol; 2013 Aug; 76(2):263-8. PubMed ID: 22506644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple benefits of targeting inflammation in the treatment of type 2 diabetes.
    Donath MY
    Diabetologia; 2016 Apr; 59(4):679-82. PubMed ID: 26868493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting IL-12 family cytokines: A potential strategy for type 1 and type 2 diabetes mellitus.
    Luo J; Ning T; Li X; Jiang T; Tan S; Ma D
    Biomed Pharmacother; 2024 Jan; 170():115958. PubMed ID: 38064968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Inflammation Through a Physical Active Lifestyle and Pharmaceuticals for the Treatment of Type 2 Diabetes.
    Knudsen SH; Pedersen BK
    Curr Diab Rep; 2015 Oct; 15(10):82. PubMed ID: 26358738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.